BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 16622268)

  • 21. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
    Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
    Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
    Nabhan C; Davis N; Bitran JD; Galvez A; Fried W; Tolzien K; Foss S; Dewey WM; Venugopal P
    Cancer; 2011 Apr; 117(7):1490-7. PubMed ID: 21425150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study.
    Lu A; Fang Y; Du X; Li Y; Cai Z; Yu K; Zhao L; Wang B; Wu J; Cheng Y; Zuo Y; Jia Y; Tan F; Ding L; Lu J; Zhang L; Huang X
    Blood Cancer J; 2016 Feb; 6(2):e400. PubMed ID: 26918364
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
    Faderl S; Balakrishnan K; Thomas DA; Ravandi F; Borthakur G; Burger J; Ferrajoli A; Cortes J; O'Brien S; Kadia T; Feliu J; Plunkett W; Gandhi V; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):231-8. PubMed ID: 24440659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
    Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
    Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
    Liu AP; Lee V; Li CK; Ha SY; Chiang AK
    Ann Hematol; 2016 Feb; 95(3):501-7. PubMed ID: 26666536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clofarabine for the treatment of acute lymphoblastic leukemia.
    Jeha S; Kantarjian H
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):113-8. PubMed ID: 17288522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine.
    Dressel A; Kwari M; McGreal AM
    Clin J Oncol Nurs; 2011 Feb; 15(1):E13-23. PubMed ID: 21278032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia.
    Baytan B; Ozdemir O; Gunes AM; Dönmez O
    J Pediatr Hematol Oncol; 2010 Mar; 32(2):144-6. PubMed ID: 20057324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea.
    Choi JY; Hong CR; Hong KT; Kang HJ; Kim S; Lee JW; Jang PS; Chung NG; Cho B; Kim H; Koh KN; Im HJ; Seo JJ; Hahn SM; Han JW; Lyu CJ; Yang EJ; Lim YT; Yoo KH; Koo HH; Kook H; Jeon IS; Cho H; Shin HY
    Cancer Res Treat; 2021 Oct; 53(4):1184-1194. PubMed ID: 33421973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
    Kantarjian H; Gandhi V; Cortes J; Verstovsek S; Du M; Garcia-Manero G; Giles F; Faderl S; O'Brien S; Jeha S; Davis J; Shaked Z; Craig A; Keating M; Plunkett W; Freireich EJ
    Blood; 2003 Oct; 102(7):2379-86. PubMed ID: 12791647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
    O'Connor D; Sibson K; Caswell M; Connor P; Cummins M; Mitchell C; Motwani J; Taj M; Vora A; Wynn R; Kearns PR
    Br J Haematol; 2011 Aug; 154(4):482-5. PubMed ID: 21689087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
    Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR
    Leukemia; 2011 Apr; 25(4):599-605. PubMed ID: 21252987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
    Larson RA
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.
    Huguet F; Leguay T; Raffoux E; Rousselot P; Vey N; Pigneux A; Ifrah N; Dombret H
    Leuk Lymphoma; 2015 Apr; 56(4):847-57. PubMed ID: 24996442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.
    Styczynski J; Gil L; Derwich K; Wachowiak J; Balwierz W; Badowska W; Krawczuk-Rybak M; Matysiak M; Wieczorek M; Balcerska A; Sonta-Jakimczyk D; Stefaniak J; Kowalczyk J; Urasinski T; Sobol G; Komarnicki M; Wysocki M
    Anticancer Res; 2009 May; 29(5):1643-50. PubMed ID: 19443380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
    Gidwani P; Ramesh KH; Liu Y; Kolb EA
    Chemotherapy; 2008; 54(2):120-4. PubMed ID: 18303261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
    Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
    Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.